Status:
COMPLETED
OCTA and Polypoidal Choroidal Vasculopathy
Lead Sponsor:
Federico II University
Conditions:
Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
60-80 years
Brief Summary
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.
Detailed Description
Polypoidal choroidal vasculopathy represents a distinct form of choroidal neovascularization. The study investigated the changes in choroidal vascular network after anti-VEGF therapy using optical co...
Eligibility Criteria
Inclusion
- age older than 60 years
- diagnosis of polypoidal choroidal vasculopathy
- absence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
- absence of significant lens opacities, low-quality OCT-A images.
Exclusion
- age older than 80 years
- absence of diagnosis of polypoidal choroidal vasculopathy
- presence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
- presence of significant lens opacities, low-quality OCT-A images.
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04714242
Start Date
January 15 2019
End Date
December 20 2020
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Naples "Federico II"
Naples, Italy, 80100